What Volitionrx Ltd does.

Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests.

Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s response to treatment.

The tests offered by Volition and its subsidiaries are designed to detect and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.

Revenue and profit, by fiscal year.

More on VNRX.

• Volitionrx Ltd summary
• Volitionrx Ltd financial statements
• Volitionrx Ltd key metrics
• Volitionrx Ltd health scores and style box
• Volitionrx Ltd earnings
• Volitionrx Ltd dividends
• Volitionrx Ltd valuation
• Volitionrx Ltd ownership and insiders
• Volitionrx Ltd peers

Figures from Volitionrx Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.